Author: Criscuolo, E.; Caputo, V.; Diotti, R. A.; Sautto, G. A.; Kirchenbaum, G. A.; Clementi, N.
Title: Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines Document date: 2019_3_4
ID: 0xo2fiop_44
Snippet: There remain a number of obstacles and drawbacks associated with each antigen delivery platform that still need to be addressed (Table 4 ). Presently there are no FDA-approved compounds for edible vaccination, but new emerging technologies like nanoparticles (NPs) could help to control antigen bioavailability to avoid mucosal tolerance. NPs are particles with a mean size of 10-100 nm (up to 2000 nm), which can be used as carriers and/or adjuvants.....
Document: There remain a number of obstacles and drawbacks associated with each antigen delivery platform that still need to be addressed (Table 4 ). Presently there are no FDA-approved compounds for edible vaccination, but new emerging technologies like nanoparticles (NPs) could help to control antigen bioavailability to avoid mucosal tolerance. NPs are particles with a mean size of 10-100 nm (up to 2000 nm), which can be used as carriers and/or adjuvants in vaccine preparation [139] [140] [141] . Moreover, NPs can be targeted to specific cell populations. As an example, NPs can be coated with antibodies recognizing a surface protein on dendritic cells [142, 143] . This approach enabled a more accurate measurement of the quantity of antigen required to elicit an immune response [144] . Finally, a more efficient immunization was demonstrated using NP-based approaches combined with an intradermal vaccine delivery [145] , while oral delivery needed further investigations as they have been tested only in vitro [146, 147] .
Search related documents:
Co phrase search for related documents- antigen delivery and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- antigen delivery and mucosal tolerance: 1
- antigen delivery and np nanoparticle: 1, 2, 3
- antigen delivery and oral delivery: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- antigen delivery and surface protein: 1, 2, 3, 4, 5, 6, 7, 8
- antigen delivery and vaccine delivery: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56
- antigen delivery and vaccine preparation: 1
- antigen delivery platform and immune response: 1, 2, 3, 4
- antigen delivery platform and surface protein: 1
- antigen delivery platform and vaccine delivery: 1, 2
- cell population and dendritic cell: 1, 2, 3, 4, 5, 6, 7
- cell population and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63
- cell population and specific cell population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
- cell population and specific cell population target: 1
- cell population and surface protein: 1, 2, 3, 4, 5
- cell population and vaccine delivery: 1
- dendritic cell and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66
Co phrase search for related documents, hyperlinks ordered by date